Roivant Sciences (ROIV) Divestments (2023 - 2024)
Roivant Sciences' (ROIV) quarterly Divestments came in at $185.6 million in Q4 2024, up 290.71% YoY from $47.5 million in Q1 2024, and up 290.71% on a QoQ basis from $47.5 million in Q4 2023.
Powered by 
Analysis
Roivant Sciences (ROIV) Divestments (2023 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 2 years of Divestments data on file, last reported at $185.6 million in Q4 2024.
- Quarterly Divestments rose 290.71% year-over-year to $185.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $233.1 million (changed N/A YoY) and the FY2025 annual result came in at $260.6 million, up 448.6% from the prior year.
- Divestments advanced to $185.6 million in Q4 2024, from $47.5 million in the prior quarter.
- In the past five years, Divestments ranged from a high of $185.6 million in Q4 2024 to a low of $47.5 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -13.21 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 25.18 Bn | 25.18 Bn | 1.16 Mn | - |